Literature DB >> 22282380

Understanding Bartter syndrome and Gitelman syndrome.

Oliver T Fremont1, James C M Chan.   

Abstract

BACKGROUND: We aim to review the clinical features of two renal tubular disorders characterized by sodium and potassium wasting: Bartter syndrome and Gitelman syndrome. DATA SOURCES: Selected key references concerning these syndromes were analyzed, together with a PubMed search of the literature from 2000 to 2011.
RESULTS: The clinical features common to both conditions and those which are distinct to each syndrome were presented. The new findings on the genetics of the five types of Bartter syndrome and the discrete mutations in Gitelman syndrome were reviewed, together with the diagnostic workup and treatment for each condition.
CONCLUSIONS: Patients with Bartter syndrome types 1, 2 and 4 present at a younger age than classic Bartter syndrome type 3. They present with symptoms, often quite severe in the neonatal period. Patients with classic Bartter syndrome type 3 present later in life and may be sporadically asymptomatic or mildly symptomatic. The severe, steady-state hypokalemia in Bartter syndrome and Gitelman syndrome may abruptly become life-threatening under certain aggravating conditions. Clinicians need to be cognizant of such renal tubular disorders, and promptly treat at-risk patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22282380     DOI: 10.1007/s12519-012-0333-9

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  32 in total

1.  Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome.

Authors:  F C BARTTER; P PRONOVE; J R GILL; R C MACCARDLE
Journal:  Am J Med       Date:  1962-12       Impact factor: 4.965

Review 2.  Profound deafness in childhood.

Authors:  Andrej Kral; Gerard M O'Donoghue
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

3.  From bench to bedside: diagnosis of Gitelman's syndrome -- defect of sodium-chloride cotransporter in renal tissue.

Authors:  H R Jang; J W Lee; Y K Oh; K Y Na; K W Joo; U S Jeon; H I Cheong; J Kim; J S Han
Journal:  Kidney Int       Date:  2006-07-12       Impact factor: 10.612

4.  Can renal tubular hypokalemic disorders be accurately diagnosed on the basis of the diuretic response to thiazide?

Authors:  Martin C Sassen; Nikola Jeck; Günter Klaus
Journal:  Nat Clin Pract Nephrol       Date:  2007-08-14

5.  Evidence for a prostaglandin-independent defect in chloride reabsorption in the loop of Henle as a proximal cause of Bartter's syncrome.

Authors:  J R Gill; F C Bartter
Journal:  Am J Med       Date:  1978-11       Impact factor: 4.965

6.  Long-term follow-up of patients with Bartter syndrome type I and II.

Authors:  Elena Puricelli; Alberto Bettinelli; Nicolò Borsa; Francesca Sironi; Camilla Mattiello; Fabiana Tammaro; Silvana Tedeschi; Mario G Bianchetti
Journal:  Nephrol Dial Transplant       Date:  2010-03-10       Impact factor: 5.992

7.  Neonatal Bartter's syndrome, indomethacin and necrotising enterocolitis.

Authors:  N Marlow; M L Chiswick
Journal:  Acta Paediatr Scand       Date:  1982-11

8.  Hypercalciuria with Bartter syndrome: evidence for an abnormality of vitamin D metabolism.

Authors:  C Restrepo de Rovetto; T R Welch; G Hug; K E Clark; W Bergstrom
Journal:  J Pediatr       Date:  1989-09       Impact factor: 4.406

9.  Indomethacin-induced colon perforation in Bartter's syndrome.

Authors:  Emel Ataoglu; Mahmut Civilibal; Ayse Ayaz Ozkul; Ipek Guney Varal; Elmas Reyhan Oktay; Elevli Murat
Journal:  Indian J Pediatr       Date:  2009-04-06       Impact factor: 1.967

Review 10.  Bartter syndrome.

Authors:  Steven C Hebert
Journal:  Curr Opin Nephrol Hypertens       Date:  2003-09       Impact factor: 2.894

View more
  20 in total

1.  Endoplasmic reticulum-associated degradation of the renal potassium channel, ROMK, leads to type II Bartter syndrome.

Authors:  Brighid M O'Donnell; Timothy D Mackie; Arohan R Subramanya; Jeffrey L Brodsky
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

2.  Gitelman syndrome combined with complete growth hormone deficiency.

Authors:  Se Ra Min; Hyun Seok Cho; Jeana Hong; Hae Il Cheong; Sung Yeon Ahn
Journal:  Ann Pediatr Endocrinol Metab       Date:  2013-03-31

Review 3.  Molecular pathophysiology of Bartter's and Gitelman's syndromes.

Authors:  Efstathios Koulouridis; Ioannis Koulouridis
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

4.  [Poor weight gain, recurrent metabolic alkalosis and hypokalemia in a neonate].

Authors:  Miao Qian; Shu-Ping Han; Zhang-Bing Yu; Xiao-Hui Chen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

5.  Accentuated hyperparathyroidism in type II Bartter syndrome.

Authors:  Daniel Landau; Evgenia Gurevich; Levana Sinai-Treiman; Hannah Shalev
Journal:  Pediatr Nephrol       Date:  2016-02-08       Impact factor: 3.714

6.  Hypercalcemia-induced hypokalemic metabolic alkalosis with hypophosphatemia in a multiple myeloma patient: lessons for the clinical nephrologist.

Authors:  Ghulam Mujtaba Ghumman; Marjan Haider; Eusha Abdul Raffay; Hassan Afzal Cheema; Amman Yousaf
Journal:  J Nephrol       Date:  2022-10-21       Impact factor: 4.393

Review 7.  Outpatient management of Gitelman's syndrome in pregnancy.

Authors:  Stephy Mathen; Michael Venning; Joanna Gillham
Journal:  BMJ Case Rep       Date:  2013-01-25

8.  Gitelman or Bartter type 3 syndrome? A case of distal convoluted tubulopathy caused by CLCNKB gene mutation.

Authors:  António José Cruz; Alexandra Castro
Journal:  BMJ Case Rep       Date:  2013-01-22

Review 9.  Renal involvement in primary Sjögren syndrome.

Authors:  Hélène François; Xavier Mariette
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

10.  Genetic analysis in Bartter syndrome from India.

Authors:  Pradeep Kumar Sharma; Bhaskar Saikia; Rachna Sharma; Kumar Ankur; Praveen Khilnani; Vinay Kumar Aggarwal; Hae Cheong
Journal:  Indian J Pediatr       Date:  2014-04-04       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.